Dopamine D(3) Receptor Antagonists. 1. Synthesis and Structure-activity Relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans
Overview
Authors
Affiliations
5,6-Dimethoxy-2-(N-dipropyl)-aminoindan (3, PNU-99194A) was found to be a selective dopamine D(3) receptor antagonist with potential antipsychotic properties in animal models. To investigate the effects of nitrogen substitution on structure-activity relationships, a series of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans were synthesized and evaluated in vitro for binding affinity and metabolic stability. The results indicate that substitution at the amine nitrogen of the 2-aminoindans is fairly limited to the di-N-propyl group in order to achieve selective D(3) antagonists. Thus, combinations of various alkyl groups were generally inactive at the D(3) receptor. Although substitution with an N-alkylaryl or N-alkylheteroaryl group yields compounds with potent D(3) binding affinity, the D(2) affinity is also enhanced, resulting in a less than 4-fold preference for the D(3) receptor site, and no improvements in metabolic stability were noted. A large-scale synthesis of the D(3) antagonist 3 has been developed that has proven to be reproducible with few purification steps. The improvements include the use of 3,4-dimethoxybenzaldehyde as a low-cost starting material to provide the desired 5,6-dimethoxy-1-indanone 5c in good overall yield (65%) and the formation of a soluble silyl oxime 17 that was reduced efficiently with BH(3).Me(2)S. The resulting amino alcohol was alkylated and then deoxygenated using a Lewis acid and Et(3)SiH to give the desired product 3 in good overall yield of ( approximately 65%) from the indanone 5c.
Discovery of dihydrooxazolo[2,3-]isoquinoliniums as highly specific inhibitors of hCE2.
Ding L, Wang L, Zou K, Li B, Song Y, Zhang Q RSC Adv. 2022; 9(61):35904-35912.
PMID: 35528066 PMC: 9074662. DOI: 10.1039/c9ra07457k.
Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease.
Chagraoui A, Di Giovanni G, De Deurwaerdere P Biomolecules. 2022; 12(2).
PMID: 35204744 PMC: 8961531. DOI: 10.3390/biom12020243.
Sundriyal S, Chen P, Lubin A, Lueg G, Li F, White A Medchemcomm. 2018; 8(5):1069-1092.
PMID: 29308121 PMC: 5708365. DOI: 10.1039/c7md00052a.
High-affinity and selective dopamine D₃ receptor full agonists.
Chen J, Levant B, Wang S Bioorg Med Chem Lett. 2012; 22(17):5612-7.
PMID: 22871578 PMC: 3461280. DOI: 10.1016/j.bmcl.2012.07.003.
Chen J, Collins G, Zhang J, Yang C, Levant B, Woods J J Med Chem. 2008; 51(19):5905-8.
PMID: 18785726 PMC: 2662387. DOI: 10.1021/jm800471h.